Antigenics, Inc. (NASDAQ:AGEN)
| CAPS Rating |
|
|---|---|
| Open | $3.60 |
| Previous Close | $3.47 |
| Daily Range | $3.54 - $3.72 |
| 52-Week Range | $1.92 - $6.72 |
| Market Cap | $69.85M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 541,767 |
| Average Daily Volume | 0 |
How do you think AGEN will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
AGEN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
AGEN News and Commentary
- Small Biotechnology Stocks Roar, Profit Now – Blog at The Motley Fool
- Biotech Ideas: Top Biotech Stocks with Bullish Institutional Trends – NASDAQ
- Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution – Minyanville
- Agenus' CEO Discusses Q2 2011 Results - Earnings Call Transcript – SeekingAlpha Transcripts
- The Cancer Conference Trade: Picking Up Biotech Bargains – NASDAQ
- The Cancer Conference Trade: Picking Up Biotech Bargains – The Motley Fool
- Roche Bests Bristol-Myers with Melanoma Study – Minyanville
- Bristol, Roche Pact Puts Spotlight on Skin Cancer – Minyanville
- A Simplified ASCO 2011 List for Biotech Investor Research – SeekingAlpha
- ASCO 2011: Opportunities for Biotech Investor Success and Failure – SeekingAlpha
- Antigenics CEO Discusses Q4 2010 Results - Earnings Call Transcript – SeekingAlpha
- Antigenics CEO Discusses Q4 2010 Results - Earnings Call Transcript – SeekingAlpha Transcripts
- 8 Cancer Innovators to Watch – SeekingAlpha
- Antigenics CEO Discusses Q3 2010 Results - Earnings Call Transcript – SeekingAlpha Transcripts
- Antigenics CEO Discusses Q3 2010 Results - Earnings Call Transcript – SeekingAlpha
- Whoa! What Just Happened to My Stock? – The Motley Fool
- Antigenics Inc. Q2 2010 Earnings Call Transcript – SeekingAlpha Transcripts
- Antigenics Inc. Q2 2010 Earnings Call Transcript – SeekingAlpha
- Antigenics: Bright Future Ahead – SeekingAlpha
- Low-Profile Stocks for High Returns – The Motley Fool

RSS Headlines
Fool UK